SUBSCRIBE
SUBSCRIBE
News   Drug Development

Basilea Pharmaceutica Presents Compelling Clinical And Preclinical Data On Its Novel Broad-Spectrum Antifungal BAL8557

June 27, 2006 | 
1 min read

BASEL, Switzerland, June 27, 2006 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (Swiss:BSLN.SW - News) presents data on its antifungal BAL8557 showing a promising safety and drug-drug interaction profile. Additional data confirms broad-spectrum antifungal activity.

Preclinical Europe
MORE ON THIS TOPIC
3D illustration of an RNA molecule
Cardiovascular disease
Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner
February 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration of two hands shaking while another hand gently grips a wrist
Collaboration
Cassava’s Stock Rises After Licensing Seizure Rights for Embattled Drug Simufilam
February 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Weigh scales on pink background, top view with space for text. Overweight concept
Weight loss
Kallyope Discreetly Drops Disappointing Data for Oral Obesity Candidate
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Regeneron logo on a light brown building
Lymphoma
Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac